Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GW433908/Ritonavir vs Nelfinavir in ART-Naive HIV-1 Infected Subjects
NCT00009061Phase 3Unknown
- Sponsor
- GSK
- Start
- Nov 2000
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of fosamprenavir in human immunodeficiency virus type 1 infection (HIV-1) (2 arms), sponsored by GSK. Primary endpoint: Magnitude and durability of antiviral response at 48 weeks. Status: unknown.
02
Drugs
fosamprenavir
03
Conditions
human immunodeficiency virus type 1 infection (HIV-1)
Beyond the preview
Go deeper on NCT00009061.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00009061.